U.S. Tech Hardware Stock News

Alkermes has entered into a new senior secured credit agreement totaling $1.525b with a group of major financial institutions. The agreement provides a significant pool of committed capital that will affect the company’s balance sheet and capital structure. The transaction is a key corporate finance development for Alkermes, trading on NasdaqGS:ALKS. For you as an investor, this financing move sits alongside a mixed share performance picture for NasdaqGS:ALKS. The stock closed at $31.91,...

Easterly Government Properties, Inc. has reported its fourth-quarter 2025 results, with revenue rising to US$87.04 million while net income eased to US$4.59 million, alongside Board approval of a US$0.45 per-share quarterly dividend payable on March 19, 2026. The combination of higher revenue but lower earnings per share highlights the tension between growth and profitability as Easterly continues to support its shareholder dividend. With revenue up year over year but earnings per share...

If you are wondering whether Dynex Capital's current share price offers good value, you are not alone, especially with income focused investors often watching mortgage REITs closely. The stock last closed at US$14.13, with returns of 0.6% over 7 days, a 3.4% decline over 30 days, 0.4% year to date, 17.4% over 1 year, 59.2% over 3 years and 35.7% over 5 years. This raises fair questions about how that performance lines up with the underlying value. Recent coverage around Dynex Capital has...

If you are looking at Cytokinetics and wondering whether the current share price actually reflects its underlying value, you are not alone. The stock most recently closed at US$67.94, with returns of 2.5% over 7 days, 7.1% over 30 days, 10.1% year to date and 41.1% over the past year, which naturally raises questions about what is already priced in and what is not. Recent attention around Cytokinetics has focused on its pipeline progress and regulatory milestones, which often influence how...

ORIC Pharmaceuticals (NasdaqGS:ORIC) reports progress in its cancer therapy pipeline, with lead drug candidates entering Phase 1b clinical trials. The company announces new collaborations with Pfizer, Bayer, and Johnson & Johnson, aimed at advancing therapies that target resistance mechanisms in cancer treatment. These developments are drawing increased investor attention as they represent material steps in ORIC Pharmaceuticals' clinical and partnership strategy. ORIC Pharmaceuticals...

Smithfield Foods (SFD) is back on investors’ radar after recent share price moves, with the stock showing mixed short term returns but stronger performance over the past month and the past three months. See our latest analysis for Smithfield Foods. The latest share price of US$25.04 sits alongside a 30 day share price return of 10.07% and a 90 day share price return of 18.50%. The 1 year total shareholder return of 24.16% points to momentum that has been building rather than fading. If recent...

Liberty Global Ltd. has reported its full-year 2025 results, with sales rising to US$4,878.5 million from US$4,341.9 million, but swinging from a net income of US$1.59 billion to a very large net loss of US$7.14 billion and a basic loss per share from continuing operations of US$20.86. The combination of higher revenue and a very large reported loss raises questions about cost structure, one-off charges, and how resilient the business model really is. We’ll now consider how this sharp move...

If you are wondering whether Corcept Therapeutics at around US$34.82 is starting to look interesting on price, you are not alone. The stock has been drawing attention from investors focused on value. The share price has seen a 12.9% decline over the last 7 days, 20.8% over 30 days, 8.8% year to date and 45.2% over 1 year, even though the 3 year and 5 year returns sit at 63.4% and 38.4% respectively. Recent coverage has largely centered on ongoing developments in its pharmaceutical and...

If you are looking at AMETEK and wondering whether the current price really reflects its underlying worth, you are not alone. The stock last closed at US$233.51, with returns of 1.6% over 7 days, 5.8% over 30 days, 11.7% year to date, 26.3% over 1 year, 69.0% over 3 years, and 104.5% over 5 years. This naturally raises questions about how much future potential or risk is already priced in. Recent coverage around AMETEK has focused on its role in the capital goods space and how investors are...

If you are wondering whether Federal Agricultural Mortgage is starting to look like value after its recent pullback, this article will walk through what the current share price might be implying about the company. The stock last closed at US$149.46, with a 14.1% decline over 7 days, a 12.7% decline over 30 days, a 15.3% decline year to date, and a 25.8% decline over the past year, while the 3 year and 5 year returns sit at 15.9% and 103.1% respectively. Recent coverage has focused on how...

Many investors are asking whether Welltower's current share price is aligned with its underlying value, or whether expectations have moved ahead of the fundamentals. The stock last closed at US$208.19, with a 1 year return of 42.6% and a 3 year return that is very large at around triple the starting point. This kind of performance can change how the market views both its growth potential and its risk profile. Recent headlines around Welltower have focused on portfolio activity, capital...

Wondering if GXO Logistics is still good value after its recent run, or if you might be late to the story? This article is aimed squarely at that question. The share price recently closed at US$65.59, with returns of 0.1% over 7 days, 14.2% over 30 days, 20.8% year to date, and 66.9% over the past year. These figures naturally raise questions about growth potential and changing risk perceptions. Recent coverage has focused on GXO Logistics' position in outsourced logistics and warehouse...

ARMOUR Residential REIT (NYSE:ARR) reported robust Q4 2025 results, highlighting portfolio growth and higher book value. The company affirmed its dividend, signaling confidence in the stability of its payout. Management outlined updated plans for capital deployment and risk management in what it views as a supportive market backdrop. The portfolio update included a focus on lower coupon and seasoned mortgage-backed securities to address prepayment risk. ARR also raised fresh capital and...

Red Rock Resorts has already reported its fourth-quarter and full-year 2025 results, showing higher revenue but slightly lower quarterly net income, and its board declared a US$1.00 per Class A share special cash dividend payable on February 27, 2026 to stockholders of record on February 20, 2026. Alongside these results, the company highlighted record fourth-quarter gaming performance in Las Vegas and outlined expansion projects and active capital allocation, underscoring management’s focus...

In February 2026, Getty Realty Corp. completed a follow-on equity offering of 4,000,000 common shares at US$32.48 per share, raising about US$129.92 million through forward sale agreements with JPMorgan Chase Bank and Wells Fargo Bank to fund acquisitions, debt repayment, and general corporate purposes. This fresh equity capital sits alongside recently reported full-year 2025 results showing higher revenue and net income year on year, and a reaffirmed quarterly dividend of US$0.485 per...

In February 2026, Bausch Health Companies reported fourth-quarter 2025 revenue of US$2,796 million and a net loss of US$112 million, alongside full-year 2025 revenue of US$10.27 billion, net income of US$157 million, and a US$145 million goodwill impairment, while also issuing 2026 revenue guidance of US$10.63–US$10.88 billion. A day later, the company and its OraPharma dental unit marked the 25th anniversary of ARESTIN, currently the only FDA-approved locally applied antibiotic adjunct for...

In February 2026, Regency Centers Corporation filed an omnibus shelf registration that covers common and preferred stock, depositary shares, warrants, purchase contracts, units, and debt securities of Regency Centers, L.P., giving it the legal framework to issue a wide range of securities as needed. This broad shelf registration expands Regency Centers’ optionality for future financing or corporate actions, which investors often watch closely for signals about potential development,...

Smurfit Westrock Plc has reported its fourth-quarter and full-year 2025 results, with quarterly sales edging up to US$7,580 million while net income fell to US$97 million, and full-year sales rising to US$31.18 billion alongside net income of US$699 million. Alongside these results, the company moved to close a paper machine and related extrusion facility in Quebec, signaling an effort to streamline its solid bleached sulfate portfolio and sharpen the competitiveness of its paperboard...

Why insiders are buying Conduent stock after recent EBITDA progress Recent insider share purchases at Conduent (CNDT), including buying by the CEO and a director, have drawn attention as the company reports higher full year 2025 adjusted EBITDA and improved margins despite lower revenue. See our latest analysis for Conduent. The insider buying comes after a sharp move in the 1 day share price return of 11.19% and a 7 day gain of 3.58%, although the 1 year total shareholder return of 57.6% and...

Caris Life Sciences: Event Context and Recent Share Performance Caris Life Sciences (CAI) has drawn investor attention recently as its share price has moved from a last close of US$19.53 while posting negative returns over the past week, month, and past 3 months. See our latest analysis for Caris Life Sciences. The recent 1 day share price return of a 6.33% decline, alongside a 30 day share price return of a 21.88% decline and year to date share price return of a 27.61% decline, suggests...

Old National Bancorp recently announced that four directors, including long-serving members reaching the age limit, will retire at the May 2026 annual meeting, while the board has amended its bylaws to allow flexible board sizing and plans to shrink from 16 to 12 members. At the same time, the company raised its quarterly common dividend by 3.6% to US$0.145 per share and affirmed preferred dividends, underscoring an emphasis on capital returns alongside governance changes and ongoing...

Ramaco Resources (METC) has been drawing attention after a sharp decline in its share price over the past month, even as its past 3 months return, one year total return, and longer term performance figures remain positive. See our latest analysis for Ramaco Resources. The recent 40.26% 1 month share price decline to US$16.56 sits against a much stronger backdrop, with a 1 year total shareholder return of 73.74% and multi year total shareholder returns still firmly positive. This suggests...

Orrum Clinical Analytics recently announced a partnership with LivaNova USA Inc. to link LivaNova’s Essenz Perfusion System with Orrum’s CORE Insights platform, enabling automatic transfer of perfusion case data for post-operative analysis and peer benchmarking. By extending Essenz data into a secure analytics environment that supports evidence-based performance improvement, the collaboration could strengthen LivaNova’s positioning in data-driven cardiopulmonary care and potentially appeal...

If you are wondering whether Ovintiv's share price still offers value at current levels, it helps to step back and look at what the market might be pricing in. The stock closed at US$50.58, with returns of 7.8% over the last 7 days, 23.3% over the last 30 days, 24.9% year to date, 20.3% over 1 year, 20.9% over 3 years, and 147.0% over 5 years. Recent news around Ovintiv has largely focused on its position in the US energy sector and how investors are weighing commodity price moves against...